DE10251019A1 - Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen - Google Patents

Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen Download PDF

Info

Publication number
DE10251019A1
DE10251019A1 DE10251019A DE10251019A DE10251019A1 DE 10251019 A1 DE10251019 A1 DE 10251019A1 DE 10251019 A DE10251019 A DE 10251019A DE 10251019 A DE10251019 A DE 10251019A DE 10251019 A1 DE10251019 A1 DE 10251019A1
Authority
DE
Germany
Prior art keywords
alkyl
het
unsubstituted
independently
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10251019A
Other languages
German (de)
English (en)
Inventor
Otmar Dr. Klingler
Reinhard Dr. Kirsch
Jörg Dr. Habermann
Klaus-Ulrich Dr. Weithmann
Christian Dr. Engel
Bernard Dr. Pirard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE10251019A priority Critical patent/DE10251019A1/de
Priority to DE50309381T priority patent/DE50309381D1/de
Priority to JP2004548752A priority patent/JP4564359B2/ja
Priority to BR0315055-0A priority patent/BR0315055A/pt
Priority to CA2504153A priority patent/CA2504153C/en
Priority to YUP-2005/0294A priority patent/RS20050294A/sr
Priority to ES03810401T priority patent/ES2298621T3/es
Priority to PL03375044A priority patent/PL375044A1/xx
Priority to KR1020057007598A priority patent/KR101050680B1/ko
Priority to DK03810401T priority patent/DK1560815T3/da
Priority to CNB2003801028057A priority patent/CN100371329C/zh
Priority to PCT/EP2003/011515 priority patent/WO2004041788A1/de
Priority to AU2003301847A priority patent/AU2003301847A1/en
Priority to PT03810401T priority patent/PT1560815E/pt
Priority to EP03810401A priority patent/EP1560815B1/de
Priority to AT03810401T priority patent/ATE388941T1/de
Priority to MXPA05004365A priority patent/MXPA05004365A/es
Priority to RU2005116847/04A priority patent/RU2344129C2/ru
Priority to PE2003001085A priority patent/PE20040605A1/es
Priority to TW092129976A priority patent/TWI316512B/zh
Priority to MYPI20034144A priority patent/MY135375A/en
Priority to ARP030103974A priority patent/AR043058A1/es
Priority to US10/700,273 priority patent/US7166609B2/en
Publication of DE10251019A1 publication Critical patent/DE10251019A1/de
Priority to ZA200502645A priority patent/ZA200502645B/en
Priority to HRP20050382AA priority patent/HRP20050382B1/hr
Priority to MA28244A priority patent/MA27412A1/fr
Priority to CO05041024A priority patent/CO5700759A2/es
Priority to NO20052628A priority patent/NO330345B1/no
Priority to HK06103488A priority patent/HK1083503A1/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE10251019A 2002-11-02 2002-11-02 Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen Withdrawn DE10251019A1 (de)

Priority Applications (29)

Application Number Priority Date Filing Date Title
DE10251019A DE10251019A1 (de) 2002-11-02 2002-11-02 Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
AT03810401T ATE388941T1 (de) 2002-11-02 2003-10-18 Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
MXPA05004365A MXPA05004365A (es) 2002-11-02 2003-10-18 Nuevas diamidas del acido pirimidin -4, 6 - dicarboxilico para la inhibicion selectiva de colagenasas.
JP2004548752A JP4564359B2 (ja) 2002-11-02 2003-10-18 選択的にコラゲナーゼを阻害する新規ピリミジン−４，６−ジカルボン酸ジアミド
CA2504153A CA2504153C (en) 2002-11-02 2003-10-18 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
YUP-2005/0294A RS20050294A (en) 2002-11-02 2003-10-18 Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
ES03810401T ES2298621T3 (es) 2002-11-02 2003-10-18 Nuevas diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenasas.
PL03375044A PL375044A1 (en) 2002-11-02 2003-10-18 Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
KR1020057007598A KR101050680B1 (ko) 2002-11-02 2003-10-18 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드
DK03810401T DK1560815T3 (da) 2002-11-02 2003-10-18 Nye pyrimidin-4,6-dicarboxylsyrediamider til selektiv inhibering af kollagenaser
CNB2003801028057A CN100371329C (zh) 2002-11-02 2003-10-18 用于选择性抑制胶原酶的新的嘧啶-4,6-二甲酸二酰胺
PCT/EP2003/011515 WO2004041788A1 (de) 2002-11-02 2003-10-18 Neue pyrimidin-4,6-dicarbonsäurediamide zur selektiven inhibierung von kollagenasen
AU2003301847A AU2003301847A1 (en) 2002-11-02 2003-10-18 Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
PT03810401T PT1560815E (pt) 2002-11-02 2003-10-18 Novas diamidas do ácido pirimidino-4,6-dicarboxílico para a inibição selectiva de colagenases
EP03810401A EP1560815B1 (de) 2002-11-02 2003-10-18 Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
DE50309381T DE50309381D1 (de) 2002-11-02 2003-10-18 Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
BR0315055-0A BR0315055A (pt) 2002-11-02 2003-10-18 Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
RU2005116847/04A RU2344129C2 (ru) 2002-11-02 2003-10-18 Новые диамиды пиримидин-4,6-дикарбоновой кислоты для селективного ингибирования коллагеназ
PE2003001085A PE20040605A1 (es) 2002-11-02 2003-10-27 Nuevas diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenesas
TW092129976A TWI316512B (en) 2002-11-02 2003-10-29 Novel pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
MYPI20034144A MY135375A (en) 2002-11-02 2003-10-30 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
ARP030103974A AR043058A1 (es) 2002-11-02 2003-10-30 Diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenasas
US10/700,273 US7166609B2 (en) 2002-11-02 2003-11-03 Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
ZA200502645A ZA200502645B (en) 2002-11-02 2005-04-01 Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
CO05041024A CO5700759A2 (es) 2002-11-02 2005-04-29 Nuevas diamidas del acido pirimidin-4, 6-dicarboxilixo para la inhibicion selectiva de colagenasas
MA28244A MA27412A1 (fr) 2002-11-02 2005-04-29 Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases
HRP20050382AA HRP20050382B1 (hr) 2002-11-02 2005-04-29 Novi pirimidin-4,6-dikarboksamidi za selektivnu inhibiciju kolagenaza
NO20052628A NO330345B1 (no) 2002-11-02 2005-05-31 Pyrimidin-4,6-dikarboksylsyrediamider, fremgangsmate for fremstilling derav samt sammensetning inneholdende minst en slik forbindelse
HK06103488A HK1083503A1 (en) 2002-11-02 2006-03-20 Novel pyrimidine-4, 6-dicarboxamides for the selective inhibition of collagenases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10251019A DE10251019A1 (de) 2002-11-02 2002-11-02 Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen

Publications (1)

Publication Number Publication Date
DE10251019A1 true DE10251019A1 (de) 2004-05-19

Family

ID=32115102

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10251019A Withdrawn DE10251019A1 (de) 2002-11-02 2002-11-02 Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen

Country Status (3)

Country Link
CN (1) CN100371329C (zh)
DE (1) DE10251019A1 (zh)
ZA (1) ZA200502645B (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2020249956A1 (en) * 2019-06-12 2020-12-17 Enterprise Therapeutics Limited Modulators of tmem16a for treating respiratory disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024319A (zh) * 2018-07-16 2023-11-10 四川科伦博泰生物医药股份有限公司 酰胺类化合物、包含其的药物组合物、其制备方法及其用途
CN110724076B (zh) * 2018-07-16 2023-09-08 四川科伦博泰生物医药股份有限公司 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (de) * 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
EP1368323B1 (en) * 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2020249956A1 (en) * 2019-06-12 2020-12-17 Enterprise Therapeutics Limited Modulators of tmem16a for treating respiratory disease
CN114269433A (zh) * 2019-06-12 2022-04-01 Tmem16A有限公司 用于治疗呼吸系统疾病的tmem16a的调节剂
CN114269433B (zh) * 2019-06-12 2024-08-02 Tmem16A有限公司 用于治疗呼吸系统疾病的tmem16a的调节剂

Also Published As

Publication number Publication date
ZA200502645B (en) 2007-02-28
CN1714083A (zh) 2005-12-28
CN100371329C (zh) 2008-02-27

Similar Documents

Publication Publication Date Title
EP0877018B1 (de) Sulfonylaminocarbonsäuren
NO330345B1 (no) Pyrimidin-4,6-dikarboksylsyrediamider, fremgangsmate for fremstilling derav samt sammensetning inneholdende minst en slik forbindelse
EP1455790B1 (de) Verwendung von pyridin-2,4-dicarbons urediamiden und pyrimid in-4,6-dicarbons urediamiden zur selektiven inhibierung von kollagenasen
EP0878467A1 (de) Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
DE10300017A1 (de) Selektive MMP 13 Inhibitoren
US7166609B2 (en) Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
DE10251019A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
EP2069288B1 (de) TARTRATDERIVATE ALS INHIBITOREN DES KOAGULATIONSFAKTORS IXa
US20050004111A1 (en) Selective MMP-13 inhibitors
EP1763515B1 (de) 4-trifluormethoxyphenoxybenzol-4'-sulfonsäuren, verfahren zu ihrer herstellung und verwendung in arzneimitteln
EP1585728B1 (de) Iminosäurederivate als inhibitoren von matrix-metalloproteinasen
EP1670766B1 (de) Bicyclische Iminosäurederivate zur Behandlung von (unter anderem) Erkrankungen des Bewegungsapparates
DE10254092A1 (de) Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
EP1483244B1 (de) Cyclische n-substituierte alpha-iminocarbonsäuren zur selektiven inhibierung von kollagenase
EP1841772B1 (de) Tetrahydrofuranderivate als inhibitoren von matrix-metalloproteinasen

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8141 Disposal/no request for examination